Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Cash from Operations of 6497000.0 for Q1 2026, up 20.27% year-over-year from 5401903.17 in Q1 2025, and down 2371.68% quarter-over-quarter from 286000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Cash from Operations history runs 7 years deep, the most recent figure standing at 6497000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 20.27% year-over-year to 6497000.0; the TTM figure through Mar 2026 stood at 17062000.0 (up 50.17% YoY), while the FY2025 annual figure was 18714000.0, up 47.28% from the prior year.
- Cash from Operations for Q1 2026 stood at 6497000.0, down from 286000.0 in the prior quarter.
- The five-year high for Cash from Operations was 286000.0 in Q4 2025, with the low at 14629000.0 in Q4 2022.
- The 5-year median for Cash from Operations is 9360000.0 (2022), against an average of 9321058.82.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 131.23% in 2022, then soared 103.3% in 2025.
- Rani Therapeutics Holdings' Cash from Operations stood at 14629000.0 in 2022, then gained by 14.7% to 12478000.0 in 2023, then soared by 30.64% to 8655000.0 in 2024, then jumped by 103.3% to 286000.0 in 2025, then tumbled by 2371.68% to 6497000.0 in 2026.
- Business Quant data shows RANI's Cash from Operations at 6497000.0 in Q1 2026, 286000.0 in Q4 2025, and 5100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | -9.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.02 Mn |
| Jun 30, 2026 | -9.02 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Dec 31, 2025 | 286,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | -5.10 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | -8.15 Mn |
| Mar 31, 2025 | -8.15 Mn |
| Dec 31, 2024 | -8.66 Mn |
| Dec 31, 2024 | -8.66 Mn |
| Sep 30, 2024 | -8.41 Mn |
| Sep 30, 2024 | -8.41 Mn |
| Jun 30, 2024 | -9.03 Mn |
| Jun 30, 2024 | -9.03 Mn |
| Mar 31, 2024 | -9.40 Mn |
| Mar 31, 2024 | -9.40 Mn |